The Roche eye drug Lucentis could work better than laser treatment to treat a common cause of blindness amongst people with diabetes, according to the US National Eye Institute. Using the drug alongside laser treatment was found to be particularly effective, according to the Diabetic Retinopathy Clinical Research Network.
Lucentis, which is known generically as Ranibizumab, is an engineered immune system particle that targets the blood vessels in the eye. The drug is already approved to treat macular degeneratio, but the potential could exist to treat millions of people suffering from diabetic eye complications .
The research team found that Lucentis was extremely effective, according to a report in the journal Ophthalmology. They reportedly commented: “After one year, nearly 50 percent of eyes treated with ranibizumab and prompt or deferred laser treatment showed a substantial visual improvement.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…